Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 126,682 |
|
|||||
| News | - | ||||||
| Day High | 1.89 | Low High |
|||||
| Day Low | 1.51 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Equillium Inc | EQ | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.25 | -13.89% | 1.55 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.89 | 1.51 | 1.89 | 1.53 | 1.80 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 812 | 126,682 | $ 1.69 | $ 214,223 | - | 0.45 - 3.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:01:28 | formt | 167 | $ 1.55 | USD |
Equillium Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 53.03M | 35.12M | - | 36.08M | -13.34M | -0.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Equillium News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EQ Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.58 | 1.89 | 1.51 | 1.74 | 64,638 | -0.03 | -1.90% |
| 1 Month | 1.92 | 1.99 | 1.32 | 1.66 | 92,998 | -0.37 | -19.27% |
| 3 Months | 1.99 | 3.25 | 1.32 | 2.40 | 231,148 | -0.44 | -22.11% |
| 6 Months | 0.52 | 3.25 | 0.45 | 1.62 | 261,168 | 1.03 | 198.08% |
| 1 Year | 0.498 | 3.25 | 0.45 | 1.30 | 200,857 | 1.05 | 211.24% |
| 3 Years | 5.90 | 7.75 | 0.45 | 2.20 | 139,735 | -4.35 | -73.73% |
| 5 Years | 6.03 | 30.20 | 0.45 | 14.62 | 411,173 | -4.48 | -74.30% |
Equillium Description
| Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. |
